FYI, your name came up at the Winnipeg in 2023 party at CapClave, as one of the organizers' personal virology expert.
As a nucleoside analog, I assume that molnupiravir will (like monoclonal antibodies) be useful mainly early in the course of disease, because once COVID-19 is severe the actual viral load is typically low and dropping. As I understand it, at that point you're dealing with the sequelae of the infection, especially the inflammatory response and collateral damage to otherwise-healthy tissues.
Merck has also said that the drug will be investigated for other RNA-viral diseases, which could be super-useful if it works.
Hi, John.
FYI, your name came up at the Winnipeg in 2023 party at CapClave, as one of the organizers' personal virology expert.
As a nucleoside analog, I assume that molnupiravir will (like monoclonal antibodies) be useful mainly early in the course of disease, because once COVID-19 is severe the actual viral load is typically low and dropping. As I understand it, at that point you're dealing with the sequelae of the infection, especially the inflammatory response and collateral damage to otherwise-healthy tissues.
Merck has also said that the drug will be investigated for other RNA-viral diseases, which could be super-useful if it works.